Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)

China flag China · Delayed Price · Currency is CNY
9.87
-0.09 (-0.90%)
Apr 17, 2026, 3:04 PM CST
Market Cap16.45B +11.7%
Revenue (ttm)2.65B +4.4%
Net Income735.19M +4.0%
EPS0.44 +4.8%
Shares Out1.67B
PE Ratio22.43
Forward PEn/a
Dividend0.25 (2.53%)
Ex-Dividend Daten/a
Volume14,518,469
Average Volume21,874,963
Open9.81
Previous Close9.96
Day's Range9.80 - 9.94
52-Week Range7.90 - 13.06
Beta0.54
RSI55.49
Earnings DateMar 31, 2026

About SHE:300009

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life det... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 2,505
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300009
Full Company Profile

Financial Performance

In 2025, SHE:300009's revenue was 2.65 billion, an increase of 4.36% compared to the previous year's 2.54 billion. Earnings were 735.19 million, an increase of 4.00%.

Financial Statements